Literature DB >> 17143632

Absence of aquaporin-4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal-appearing white matter.

Colin Sinclair1, John Kirk, Brian Herron, Una Fitzgerald, Stephen McQuaid.   

Abstract

Aquaporin-4 (AQP4) has recently been implicated in the pathogenesis of neuromyelitis optica (NMO) where it has been identified as the first defined autoantigen pertinent to an inflammatory demyelinating disorder of the human CNS. Furthermore, a recent case report has shown a lack of AQP4 expression in the spinal cord lesions of NMO. However, the pattern of AQP4 expression in multiple sclerosis (MS) tissues has not been well-defined. In the present investigation we have confirmed a lack of expression of AQP4 in optic and spinal cord lesions in NMO which contrasted sharply with the increased levels of AQP4 expression seen in MS lesions. Furthermore a detailed immunohistochemical and semi-quantitative analysis is used to describe the expression pattern of AQP4 on well-characterized tissue microarray samples of MS and control white matter. Anatomically AQP4 was more highly expressed in all categories of MS tissue compared to normal control tissues with the most abundant expression in active lesions. Within active lesions AQP4 expression was significantly correlated with expression of the pro-inflammatory cytokine osteopontin. At the cellular level dual-labeling immunofluoresence demonstrated that increased expression of AQP4 was most pronounced at the astrocytic endfeet but was also associated with the cell bodies of astrocytes in the tissue parenchyma. The finding of increased AQP4 expression in MS lesions in contrast to the lack of expression in NMO lesions may suggest different mechanisms of initiation and progression between the two disease states.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17143632     DOI: 10.1007/s00401-006-0169-2

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  29 in total

Review 1.  The contribution of astrocytes to the neuroinflammatory response in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Roberta Brambilla
Journal:  Acta Neuropathol       Date:  2019-03-07       Impact factor: 17.088

Review 2.  The pathological spectrum of CNS inflammatory demyelinating diseases.

Authors:  Wei Hu; Claudia F Lucchinetti
Journal:  Semin Immunopathol       Date:  2009-09-25       Impact factor: 9.623

3.  Aquaporin-4 autoantibodies in neuromyelitis optica spectrum disorders: comparison between tissue-based and cell-based indirect immunofluorescence assays.

Authors:  Koon H Chan; Jason S C Kwan; Philip W L Ho; Jessica W M Ho; Andrew C Y Chu; David B Ramsden
Journal:  J Neuroinflammation       Date:  2010-09-07       Impact factor: 8.322

Review 4.  CD19 as a molecular target in CNS autoimmunity.

Authors:  Olaf Stüve; Clemens Warnke; Krystin Deason; Martin Stangel; Bernd C Kieseier; Hans-Peter Hartung; Hans-Christian von Büdingen; Diego Centonze; Thomas G Forsthuber; Volker Knappertz
Journal:  Acta Neuropathol       Date:  2014-07-04       Impact factor: 17.088

Review 5.  Functions of aquaporins in the eye.

Authors:  A S Verkman; Javier Ruiz-Ederra; Marc H Levin
Journal:  Prog Retin Eye Res       Date:  2008-05-22       Impact factor: 21.198

6.  Novel variants in human Aquaporin-4 reduce cellular water permeability.

Authors:  Marco D Sorani; Zsolt Zador; Evan Hurowitz; Donghong Yan; Kathleen M Giacomini; Geoffrey T Manley
Journal:  Hum Mol Genet       Date:  2008-05-29       Impact factor: 6.150

Review 7.  Neuromyelitis optica: diagnosis, pathogenesis, and treatment.

Authors:  Bruce Cree
Journal:  Curr Neurol Neurosci Rep       Date:  2008-09       Impact factor: 5.081

Review 8.  The treatment of neuromyelitis optica.

Authors:  Markus C Kowarik; John Soltys; Jeffrey L Bennett
Journal:  J Neuroophthalmol       Date:  2014-03       Impact factor: 3.042

9.  The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients.

Authors:  Ulisses C Linhares; Patrícia B Schiavoni; Priscila O Barros; Taissa M Kasahara; Bruna Teixeira; Thais B Ferreira; Regina Alvarenga; Joana Hygino; Morgana M M Vieira; Vera Carolina B Bittencourt; Regis M Andrade; Arnaldo F Andrade; Cleonice A M Bento
Journal:  J Clin Immunol       Date:  2012-09-05       Impact factor: 8.317

Review 10.  Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

Authors:  S Jarius; B Wildemann; F Paul
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.